Racial Disparities in Prostate Ca Recurrence

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

Black men are more likely than white men to have a prostate cancer recurrence after radical prostatectomy, Hadley M. Wood, MD, reported at the 2006 Prostate Cancer Symposium (abstract 138).

SAN FRANCISCO—Black men are more likely than white men to have a prostate cancer recurrence after radical prostatectomy, Hadley M. Wood, MD, reported at the 2006 Prostate Cancer Symposium (abstract 138). Dr. Wood is a resident at the Glickman Urological Institute of the Cleveland Clinic Foundation. This prospective study assessed biochemical failure rates in 2,910 men of both races during two time periods: the "early PSA period" (1987-1997) and the "later PSA period" (1998-2004). The men were followed for at least 12 months after surgery, with biochemical failure defined as PSA more than 0.2 ng/mL. Both groups were more likely to have organ-confined disease during the later PSA period; rates increased from 54% in the early period to 76% in the later period for black men (P = .0001) and from 50% to 71% for white men (P < .0001). Progression-free survival (PFS) at 5 years increased in both groups between the two periods, from 67% to 71% for blacks and from 78% to 82% for whites. The difference in PFS between the races, however, remained constant at 11% during both periods. Dr. Wood said this difference occurred even though black men were more likely to have organ-confined disease, and both groups had similar Gleason scores, clinical T stage, and initial PSA level.

Recent Videos
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content